Slide 1: Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2026
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2026 (FY2025) PHC Holdings Corporation February 12, 2026 Tokyo Stock Exchange Prime Market | 6523
Slide 2: Disclaimer
Disclaimer This document was prepared by PHC Holdings Corporation (referred to as the “Company,” herein) solely for informational purposes. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in the United States, Japan, or any other
Slide 3: Contents
Contents 01 Executive Summary 02 FY25Q3 Financial Results Summary 03 FY25 Full Year Forecasts 04 Appendix ©PHC Holdings Corporation 2026 • Corporate functions have been reviewed. Please refer to page 25 for details. • For the meanings of business-related and financial terms and abbreviations, please
Slide 4: Executive Summary
01 Executive Summary PpHe
Slide 5: FY25Q3 Financial Highlights
FY25Q3 Financial Highlights Revenue and operating profit increased YoY, driven by strong performance in the BGM business. However, a cumulative FX loss of JPY 10.5 billion, including primarily unrealized valuation losses, resulted in a YoY decrease in profit attributable to owners of parent. FY25 (J
Slide 6: Update on Diabetes Management
Update on Diabetes Management Business transfer in the U.S. was completed FY24 FY25 on January 1, 2026. （JPY in100 millions） Actual Forecast CGM CGM Performance Revenue 30.6 36.0 Business in Europe will continue for a period based on Operating profit -90.0 -64.0 TSAs*1, but there is no profit/lo
Slide 7: Progress of Initiatives in the Value Creation Plan
Progress of Initiatives in the Value Creation Plan Initiatives for Re-acquisition of ISO15189 Accreditation “Structural Reform to Strengthen the Profit Base” at the Central Laboratory February 1, 2025 Re-certified for the Medical-Related Services Mark Cost optimization: “Smart Spend Program” June
Slide 8: FY25Q3 Financial Results Summary
02 FY25Q3 Financial Results Summary
Slide 9: FY25Q3 Results
FY25Q3 Results FY24Q3 FY25Q3 FY24 FY25 YoY YoY YTD YTD Q3 Q3 Variance Variance (JPY in 100 millions) Results Results Results Results Revenue 2,669 2,693 +23 930 959 +28 Operating Profit 170 171 +1 78 67 -11 Profit Before Tax 125 25 -100 51 16 -35 Profit Attributable to Owners of Parent 76 7 -69 35 1
Slide 10: Quarterly Trends in Revenue and Operating Profit
Quarterly Trends in Revenue and Operating Profit Revenue tends to increase in the latter half of the fiscal year due to seasonality. This quarter again saw solid performance in BGM, coupled with higher demand for the Biomedical business, resulting in increased revenue and profit compared to Q2. On a
Slide 11: Revenue by Segment and Business Unit
Revenue by Segment and Business Unit FY24Q3 FY25Q3 Revenue Composition Variance YTD YTD (JPY in 100 millions) Excluding Excluding (JPY in 100 millions) Results Results FX Impact Results FX Impact 2% Diabetes Management 742 771 758 +3.9% +2.1% Healthcare Solutions 942 952 952 +1.1% +1.1% 29% 34% LSIM
Slide 12: Analysis of Revenue Growth and Operating Profit Growth
Analysis of Revenue Growth and Operating Profit Growth (JPY in 100 millions) Revenue Revenue Growth Rate +0.4% +8 +13 +12 2,693 2,669 +16 +22 2,680 -11 -6 -16 -15 FY24Q3 Diabetes LSIM Healthcare IT CRO Pathology Biomedical IVD HQ & FY25Q3 FX Impact FY25Q3 YTD Management Solutions Others YTD YTD Excl
Slide 13: [Diabetes Management Segment] Revenue and Operating Profit
[Diabetes Management Segment] Revenue and Operating Profit Despite the market decline, revenue grew YoY due to the robust performance of BGM in Europe and the U.S., contributions from CGM, and favorable FX impact against the euro. Operating profit grew significantly, driven by higher BGM revenue, en
Slide 14: [Healthcare Solutions Segment] Revenue and Operating Profit
[Healthcare Solutions Segment] Revenue and Operating Profit Revenue increased YoY, driven by higher sales from genetic testing in LSI Medience and EMR/medical-receipt systems in Healthcare IT Solutions, which offset declines in e-prescription product sales and CRO business revenue. However, despite
Slide 15: [Diagnostics & Life Sciences Segment] Revenue and Operating Profit
[Diagnostics & Life Sciences Segment] Revenue and Operating Profit Despite increased revenue in Europe due to solid performance in the Pathology business and favorable FX, overall revenue declined due to slow equipment demand in the U.S., lower revenue in IVD, and the absence of one-time income reco
Slide 16: Revenue by Region
Revenue by Region In Japan, despite growth in Healthcare IT Solutions and LSIM, revenue remained flat YoY due to declines in CRO and IVD. In Europe, revenue increased due to solid performance in BGM and Pathology, as well as favorable FX. In North America, despite growth in Diabetes Management, reve
Slide 17: Reconciliation for Adjusted EBITDA
Reconciliation for Adjusted EBITDA FY24Q3 YTD Results FY25Q3 YTD Results HQ & HQ & DM HS D&LS Consolidated DM HS D&LS Consolidated Others Others (JPY in millions) Operating Profit* 10,544 5,959 6,722 -6,197 17,028 14,737 4,929 2,337 -4,895 17,108 + Depreciation 4,951 7,445 8,458 484 21,338 3,524 7,8
Slide 18: Key Consolidated Balance Sheet Information
Key Consolidated Balance Sheet Information Goodwill increased by JPY 13.8 billion due to FX impact. Despite a net repayment of JPY 16.8 billion, the debt balance decreased by JPY 8.8 billion due to FX effects. Borrowings maturing in June 2026 were booked as current liabilities. (JPY in 100 millions)
Slide 19: FY25Q3 YTD Consolidated Cash Flow
FY25Q3 YTD Consolidated Cash Flow Operating CF totaled JPY +27.2 billion due to improved working capital, among other factors. Financing CF was JPY -22.6 billion, primarily due to JPY 16.8 billion in debt repayments and JPY 5.1 billion in dividend payments. Total CF amounted to JPY -1.1 billion, but
Slide 20: FY25 Full Year Forecasts
03 FY25 Full Year Forecasts PpHe
Slide 21: FY25 Full Year Consolidated Forecasts
FY25 Full Year Consolidated Forecasts FY25 FY25 Change from FY24 YoY Forecast Forecast Previous Comments Results Variance (JPY in 100 millions) (As of Nov) (As of Feb) Forecast Revenue 3,616 3,631 3,631 +15 - Operating Profit 226 200 200 -26 - Profit Before Tax 188 80 44 -144 -36 Profit Attributable
Slide 22: FY25 Full Year Segment Forecasts
FY25 Full Year Segment Forecasts (no change from previous forecast) FY24 FY25 YoY YoY Results Forecast Variance* Variance* (%) (JPY in 100 millions) Diabetes Management 987 990 +3 +0.3% Healthcare Solutions 1,283 1,313 +30 +2.3% Revenue Diagnostics & Life Sciences 1,309 1,281 -28 -2.2% HQ & Others 3
Slide 23: Updates on Impacts of U.S. Tariff Actions
Updates on Impacts of U.S. Tariff Actions Assumptions as of May Current Status As for the potential risk after mitigation, the Q1 Results estimated annual impact is JPY 1.0-1.5 billion • P&L impact is approx. JPY 200 million • Optimization of supply chain is progressing as planned. Mitigation
Slide 24: Appendix
04 Appendix PpHe
Slide 25: Impact of Corporate Function Review
Impact of Corporate Function Review Starting in FY25, following the review of our corporate functions and the transfer of some headquarters roles to each business, the year-on-year variances include the impact of this change. The impact amounts for each segment are as follows. FY25Q3 FY24 FY25 YoY I
Slide 26: FX Gains and Losses Recognized in Financial Income and Expenses
FX Gains and Losses Recognized in Financial Income and Expenses FX gains and losses resulting from the settlement and FX valuation of receivables and payables denominated in foreign currencies. • FX valuation losses included in financial expenses for FY25 Q3 YTD: JPY 10.5 billion (Q1: JPY 4.4 bill
Slide 27: FX Sensitivity
FX Sensitivity PHC Group is exposed to the following impacts on its full year results depending on the respective change in exchange rates (depreciation of JPY 1 throughout the year). (JPY in millions) Currencies Pair Revenue Operating Profit JPY/EUR +400 0 JPY/USD +550 +35 ©PHC Holdings Corporati
Slide 28: Glossary
Glossary Business DM Diabetes Management HS Healthcare Solutions D&LS Diagnostics & Life Sciences BGM Blood Glucose Monitoring CGM Continuous Glucose Monitoring IVD In Vitro Diagnostics Finance* EBITDA EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities) A
Slide 29: Historical Financial Data
Historical Financial Data The following data are available on our website. Quarterly Data From FY23 to FY25Q3 Include: Consolidated Balance Sheet Profit & Loss including adjustment items Cash Flow Statement Segment Revenue, Operating Profit, Adjusted EBITDA including adjustment items Reven
Slide 30: DHc GROUP
DHc GROUP